Matinas BioPharma (MTNB) announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as ...

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith ...

Corporate reorganizations are nothing new, but the targeted reorganization of HEOR groups comes at a time of significant change in the operational and competitive landscape for biopharma.

Featured here, the Income Statement (earnings report) for Matinas BioPharma Holdings Inc, showing the company's financial performance from operating and non operating activities such as revenue, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The round is the second-largest in 2025 among the nearly two dozen venture firms tracked by BioPharma Dive. Eikon has now secured about $1.1 billion in venture dollars since its inception in 2019.

Benitec Biopharma Inc. (NASDAQ:BNTC), a clinical-stage biotechnology company with a market capitalization of $264 million, is making waves in the gene therapy space with its... ByInvesting.com • 17 ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

NEW YORK - Investment firm 111 Equity Group, LLC and its principal have increased their collective ownership stake in Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) to... 111 Equity Group ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that had ...

Aspire Biopharma Holdings, Inc. ("Aspire Biopharma") is scheduled to begin trading on Nasdaq on February 20, 2025 under the ticker symbol "ASBP". HUMACO, PR AND NEW YORK, NY / ACCESS Newswire ...

NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism ...